Recent studies have suggested that prostaglandin E2 (PGE2) subtype receptors (EP) are involved in cellular proliferation and tumor development. We studied the role of EP1 and EP4 PGE2 subtype receptor antagonists AH-6809 and AH-23848B, respectively, in serum-induced 3T6 fibroblast proliferation. This was significantly reduced in a dose-dependent manner (IC50 ϳ100 and ϳ30 M, respectively) to an almost complete inhibition, without any cytotoxic effect. However, the effect of each antagonist on 3T6 cell cycle progression clearly differed. Whereas the EP1 antagonist increased the G0/G1 population, the EP4 antagonist brought about an accumulation of cells in early S phase. These effects were associated with a decrease in cyclin D and E levels in AH-6809-treated 3T6 cells and lower cyclin A levels in AH-23848B-treated fibroblasts with respect to control cells. The G0/G1 accumulation caused by AH-6809 seems to be intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) dependent, because a 6-h 1 M thapsigargin treatment allowed G 0/G1-arrested cells to enter S phase. Similarly, treatment with 20 M forskolin for 6 h allowed S-phase and G 2/M progression of AH-23848B-treated cells. This study shows that the inhibitory effect of the EP 1 and EP4 antagonists on serum-induced 3T6 fibroblast growth is due to their effect at various levels of the cell cycle machinery, suggesting that PGE 2 interaction with its different subtype receptors regulates progression through the cell cycle by modulating cAMP and [Ca 2ϩ ]i. arachidonic acid; cyclooxygenase; prostaglandin G/H synthase; phospholipase A 2
arachidonic acid; cyclooxygenase; prostaglandin G/H synthase; phospholipase A 2 ARACHIDONIC ACID (AA) is predominantly esterified in the phospholipids of membranes, and it is mobilized by phospholipases, especially phospholipases A 2 (PLA 2 s). Once released, free intracellular AA can be oxydized via three major metabolic pathways: the prostaglandin G/H synthase (PGHS), the lipoxygenase, and the cytochrome P-450 monooxygenase pathways. Thus AA is the precursor of a large number of biologically active molecules collectively named eicosanoids (34) . PGHS, also known as cyclooxygenase, catalyzes the conversion of AA to prostaglandin H 2 (PGH 2 ), the immediate precursor of prostanoids. Two isoforms of PGHS have been identified and cloned in eukaryotic cells (30) . PGHS-1 is encoded by a housekeeping gene and is thought to be involved in the maintenance of physiological functions, whereas the expression of PGHS-2 is induced by various stimuli, including mitogens, cytokines, and bacterial lipopolysaccharides (17) . The overexpression of PGHS-2 has been associated with a variety of proliferative diseases, such as colorectal, gastric, and breast cancer (12) .
Prostanoids have numerous physiological effects (48) , including cell proliferation and differentiation. PGEs induce DNA synthesis in Swiss 3T3 fibroblasts (41) . Furthermore, enhanced synthesis of PGE 2 was observed in human breast cancer, in experimental murine mammary tumor tissues (45, 52) , and in human colon cancer tissue, compared with surrounding normal mucosa (39) . PGE 2 also may inhibit programmed cell death and enhance the tumorigenic potential of colonic epithelial cells (47) . We also have suggested elsewhere that PGE 2 , the major cyclooxygenase pathway metabolite produced by fibroblasts (22) , controls 3T6 fibroblast growth and that PGHS-2 is the isoform responsible for serum-induced PGE 2 synthesis in these cells (29) .
The four subtypes of PGE receptors (EP 1 , EP 2 , EP 3 , and EP 4 ) from various species, previously defined pharmacologically, have recently been cloned (see Ref. 33 for review). They are encoded by a distinct gene and differ in their amino acid identities, pharmacological characteristics, and signal transduction properties. The unique coupling of EP subtypes to a given signal transduction pathway provides the molecular basis for the diverse and complex physiological roles of PGE 2 . Thus binding of PGE 2 to its receptor alters the levels of second messengers such as intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) (61) and cAMP (41) . Several studies have suggested the role of PGE 2 receptors in cellular proliferation and tumor development. The EP 3 subtype PGE 2 receptor is responsible for the proliferative effect of PGs on rat hepatocytes (16) . Experiments on EP 1 -deficient mice show that this subtype receptor is required for the development of preneoplastic lesions induced in colon epithelium by the carcinogen azoxymethane (56) . The same authors have proposed a chemopreventive effect of the EP 1 -selective antagonist ONO-8713 on colon cancer (55) .
We aimed to clarify the role of PGE 2 interaction with EP 1 and EP 4 subtype receptors in 3T6 fibroblast growth. Both EP 1 and EP 4 are expressed in murine fibroblasts (57) . To that end, we used specific antagonists, AH-6809 as an EP 1 antagonist (8) and AH-23848B to block PGE 2 interaction with its EP 4 receptor (5). The EP 1 receptor mediates PGE 2 -induced elevation of free Ca 2ϩ , whereas the EP 4 receptor is coupled to G s and mediates increases in cAMP concentration by activation of adenylyl cyclase (9) . Both Ca 2ϩ and cAMP play a pivotal role as mediators of cell cycle progression. The Ca 2ϩ signaling system is believed to activate the immediate-early genes responsible for inducing resting cells to reenter the cell cycle (2) . On the other hand, the contribution of the cAMP signaling pathway to cell growth seems to be dependent on both cell type and cell cycle status. Progression through the mammalian cell cycle is controlled at various levels by cyclins, cyclin-dependent kinases (Cdks), and cyclindependent kinase inhibitors (CKIs) (38) . Cdks form a binary system composed of an inactive catalytic subunit (Cdk), which is activated by its binding to the regulatory subunit (cyclin). Thus the first level of regulation of its activity is cyclin availability, which is controlled by transcriptional regulation, mRNA stability, and ubiquitin-dependent degradation. Cdk activity also is dependent on positive and negative regulatory phosphorylations and Cdk inhibitors: the Cip/Kip family, which downregulates the activity of all cyclin-Cdk complexes, and the INK4 family, which includes specific inhibitors of Cdk4 and 6. Cyclin D family members control cell cycle exit (62) and are essential components of an early G 1 checkpoint (37). Their expression depends on continuous mitogenic stimulation. Progression through G 1 of the cell cycle is governed by cyclin D-Cdk4/6 complexes in early G 1 phase and cyclin ECdk2 complexes in late G 1 (for review see Ref. 15) . Cyclin E mRNA and protein begin to accumulate in late G 1 , peak at the G 1 /S transition, and are downregulated during S phase (23) . Cdk-2-cyclin E activity is required for progression to S phase (36) . At the G 1 -S phase transition, the tumor suppressor pRB, product of the retinoblastoma gene, is inactivated by hyperphosphorylation by the complex cyclin D-Cdk4/6, which allows the transcription factor family E2F to activate E2 site-containing gene promoters (see Ref. 13 for review), leading to S-phase gene trancription. Cyclin A is an S-phase cyclin, which, with its partner Cdk2, associates with the transcription factor E2F1/DP1. This association is crucial for the transit of cells through the S-phase checkpoint (25) .
Our results suggest that interaction of PGE 2 with both EP 1 Cell culture. Murine 3T6 fibroblasts (ATCC CCL96) were grown, as described elsewhere (29) , in RPMI 1640 containing 10% FCS (10% FCS-RPMI), penicillin (100 U/ml), and streptomycin (100 g/ml) in a humidified atmosphere of 95% air-5% CO 2 at 37°C. Cells were harvested with trypsin/EDTA and passed to tissue culture 100-or 60 mm-dishes (Costar, Cambridge, MA) for experimental purposes.
Cell growth. The effect of prostanoid receptor antagonists was assessed on 3T6 fibroblasts plated at 10 4 cells/well in 12-well plates (Costar) and cultured for 24 h in 10% FCS-RPMI. Cells were incubated for 2 days in 10% FCS medium in the presence of the different treatments. At the end of the experiments, cells were washed, trypsinized, and counted by using ethidium bromide/acridine orange staining to assess viability. To study cell recovery, after a 24-h treatment with AH-6809 or AH-23848B, 3T6 fibroblast cultures were washed with phosphate-buffered saline solution (PBS) and fresh 10% FCS medium was added. Growth recovery was assessed after 1, 2, or 3 days by counting trypsinized cells, as mentioned above.
Fluorescence-activated cell sorting analysis/flow cytometry cell cycle analysis. Cells were seeded, and 24 h later they were washed with PBS and serum starved. After 24-h serum starvation, the percentage of cells in G 0/G1 was ϳ80%. Cells were then cultured in 10% FCS-RPMI containing the treatments. After 30 h, cells were trypsinized, fixed with 70% ethanol, and stored at 4°C for at least 2 h. Thapsigargin and forskolin were added to the AH-6809 or AH-23848B-containing culture medium after a 30-h incubation, and 6 h later cells were harvested and fixed. They were then stained for 1 h at room temperature with a 20 g/ml PI solution in PBS containing 0.1% Triton X-100 (Sigma) and 0.2 mg/ml DNasefree RNase A. Cells were analyzed on an Epics XL flow cytometer (Coulter, Hialeah, FL). The instrument was set up with the standard configuration: excitation of the sample was performed with a standard 488-nm air-cooled argon-ion laser at 15 mV. Forward scatter, side scatter, and red (620 nm) fluorescence for PI were acquired. Optical alignment was based on optimized signal from 10-nm fluorescent beads (Immunocheck, Epics Division). Time was used as a control of the stability of the instrument. Red fluorescence was projected on a 1024 monoparametrical histogram. Aggregates were excluded by gating single cells by their area vs. peak fluorescence signal. DNA was analyzed (Ploidy analysis) on single fluorescence histograms by using Multicycle software (Phoenix Flow Systems, San Diego, CA).
Protein determination. Total protein was measured by the Bradford method (3), using the Bio-Rad protein assay (Hercules, CA) with BSA as standard.
Western blot analysis. 3T6 fibroblast cultures were washed twice with ice-cold PBS. Total cellular fraction was obtained by scraping off the cells in lysis buffer containing 200 mM Tris ⅐ HCl, 200 mM NaCl, 2% Igepal CA-630, 400 M NaF, 200 M DTT, and 400 M Na 3VO4, followed by incubation for 30 min at 4°C. Immunoblot analysis for cyclins was performed as follows: 20 g of protein from cell lysates were separated by a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel (26) and blotted for 1 h with a constant voltage of 100 V onto a polyvinylidene difluoride membrane (Immun-Blot PVDF membrane, 0.2 m; Bio-Rad) using a MiniProtean II system (Bio-Rad). A prestained SDS-PAGE protein standard (Bio-Rad) was used to check transfer efficiency and as a molecular weight marker. Membranes were blocked with 5% nonfat milk powder in 0.1%Tween 20-PBS for 1 h. A rabbit polyclonal antibody against cyclin D, E, or A was applied in a 1:200 dilution for 1 h. The blot was washed several times with 0.1% Tween 20-PBS and incubated with a goat anti-rabbit antibody in a 1:2,000 dilution for 1 h. Antibody binding was visualized with an enhanced chemiluminiscence kit (Supersignal West Dura Extended Duration Substrate) from Pierce (RocKford, IL) using Bio Max Light-2 film.
Statistical analysis. Results are expressed as means Ϯ SE. Differences between nontreated and treated cells were tested by using Student's t-test followed by the least significant difference test as appropriate. 4 subtype PGE 2 receptor antagonists in serum-induced 3T6 fibroblast proliferation. To determine the role of PGE 2 on 3T6 fibroblast proliferation through the interaction with its G protein-coupled receptors, EP 1 and EP 4 , the cells were cultured in 10% FCS-RPMI in the presence of the antagonists AH-6809 and AH-23848B, respectively (5, 8), for 48 h.
RESULTS

Effect of EP 1 and EP
Cell growth was significantly reduced by both compounds in a dose-dependent manner (Fig. 1) . The IC 50 of AH-6809 (ϳ100 M) was higher than that of AH-23848B (ϳ30 M). Interestingly, both antagonists almost completely inhibited cell growth at the highest doses used. The above-mentioned treatments did not cause cytotoxicity at the concentrations and for the periods of time assayed, as was assessed by observing morphological appearance of the cells by light microscopy and ethidium bromide/acridine orange staining. Moreover, once the treatments were removed from the culture medium, cells recovered the growth (Figs. 2  and 3 ), although AH-23848B-treated cells did so at a slower rate. Thus the effect of these antagonists is due to growth inhibition and not to the cytotoxic effect of the treatments.
Effect of EP 1 and EP 4 subtype PGE 2 receptor antagonists on cell cycle distribution of 3T6 fibroblasts. Next, we determined the effect of EP 1 and EP 4 antagonists on cell cycle progression of 3T6 fibroblasts. 3T6 fibroblast cultures that had been G 0 /G 1 synchronized by overnight serum starvation were incubated with 10% FCS medium containing AH-6809 or AH-23848B for 30 h, a period of time that corresponds to approximately two cycles in 3T6 cells. Cell cycle distribution was analyzed by DNA staining with PI, followed by fluorescence-activated cell sorting (FACS) analysis.
Treatments with the EP 1 antagonist were associated with a significant increase in G 0 /G 1 population (from 32 Ϯ 3% in control cells to 61 Ϯ 11% in 150 M AH-6809-treated cells) and a decrease in S-phase population (from 53 Ϯ 3% in control cells to 30 Ϯ 9% in 150 M AH-6809-treated cells) (Fig. 4) . On the other hand, the EP 4 antagonist AH-23848B brought about a significative accumulation of cells in S phase. The S-phase population increased from 53 Ϯ 3% in control cells to 86 Ϯ 5% in 100 M AH-23848B-treated cells, and there was a decrease in G 2 /M (to 3 Ϯ 2%, compared with 13 Ϯ 0.5% in control cells) and G 0 /G 1 population (from 32 Ϯ 3% in control cells to 10 Ϯ 2% in 100 M AH-23848B-treated cells) (Fig. 4) . These results indicate that both antagonists inhibit serum-induced 3T6 fibroblast growth at distinct levels of the cell cycle, suggesting that PGE 2 specifically regulates cellular proliferation in these cells by interaction with its different subtype receptors. Interestingly, when 24-h serum-starved synchronized 3T6 fibroblasts (80 Ϯ 5% in G 0 /G 1 , 15 Ϯ 4% in S, and 5 Ϯ 4% in G 2 /M) were treated with 10% FCS media in the presence of both antagonists (30 M AH-23848B and 100 M AH-6809), cells went through G 1 and finally accumulated in S phase (78 Ϯ 5%), whereas a very low percentage remained in G 2 /M (1 Ϯ 0.5%). This suggests that the S-phase arrest induced by the EP 4 antagonist is stronger and more limiting than the G 0 /G 1 arrest induced by the EP 1 antagonist, because AH-6809 plus AH-23848B treatment barely allowed G 0 /G 1 -synchronized cells to complete S phase, whereas they seemed to progress through G 0 /G 1 and enter in S phase, although more slowly than control cells.
Finally, note that none of the treatments we applied caused a population of cells with DNA content less than 2n, as would be expected if some of them induced cell apoptosis.
Effect of AH-6809 and AH-23848B on cyclin levels. Progression of the mammalian cell cycle is governed by cyclins, Cdks, and CKIs (38) . Cdks form a binary system composed of the inactive catalytic subunit Cdk, which is activated by binding to cyclin. We aimed to determine whether the impaired progression through the cycle of EP 1 or EP 4 antagonist-treated cells was linked to changes in G 1 and S phase cyclin levels, which control transition between the phases of the cell cycle in association with Cdks.
The levels of cyclin D, E, and A protein were low in quiescent 3T6 cells. Exposure of these cells to 10% FCS-containing media caused a time-dependent increase of cyclin D (maximum value within 6-18 h), cyclin E (maximum value within 4-10 h), and, thereafter, cyclin A protein (maximum value at 18 h) (Fig.  5) . We next determined the effect of 150 M AH-6809 and 100 M AH-23848B on serum-induced cyclin D, E, and A expression in G 0 /G 1 -synchronized 3T6 fibroblast cultures after 6, 6, and 18 h, respectively, of serumcontaining medium addition, time points at which a significant and consistent expression of these cyclins was observed. As shown in Fig. 6 , AH-6809 significantly reduced cyclin D and E levels, whereas AH-23848B had no effect on the levels of these cyclins. In contrast, this compound significantly decreased cyclin A expression without affecting cyclin D and E levels (Fig. 6) .
Our results indicate that AH-6809 and AH-23848B interfere with cell cycle progression, resulting in growth arrest in defined phases and impaired cyclin levels. Both EP 1 (Fig. 7) . Similarly, forskolin (20 M) treatment allowed 100 M AH-23848B-treated 3T6 fibroblasts cultures arrested in early S phase to progress through the cell cycle (49 Ϯ 0.5% of cells in S phase compared with 86 Ϯ 5% without forskolin treatment). The effect of thapsigargin and forskolin on cell cycle progression was correlated with a recovery of 3T6 cell growth (Table 1) . These results support the hypothesis that PGE 2 governs progression through distinct stages of the cell cycle and proliferation of serum-stimulated 3T6 fibroblasts by regulating [Ca 2ϩ ] i and cAMP levels.
DISCUSSION
The PGHS pathway of the AA cascade have been suggested to play a pivotal role in cell proliferation and in the development of numerous human tumors, such as colon, breast, and lung carcinoma (12) .
Murine fibroblasts have served as a model system for the study of the regulation of mitogenesis. We have reported elsewhere that a Ca 2ϩ -independent cytosolic PLA 2 is involved in serum-induced 3T6 fibroblast proliferation (43) . Furthermore, in these cells, PGE 2 , which is synthesized mainly by the inducible form of PGHS, plays a key role in the control of FCS-induced growth (29) . On the other hand, PGs have been shown to stimulate 3T3 fibroblast DNA synthesis via PGF 2␣ receptor (FP), EP 1 subtype receptor, and PGI 2 (IP) through Ca 2ϩ -and cAMP-dependent pathways (57) . We aimed to elucidate the effect of PGE 2 interaction with its EP 1 and EP 4 subtype receptors on the control of serum-induced 3T6 fibroblast proliferation and on progression through the cell cycle. Both EP 1 and EP 4 PGE 2 subtype receptors have been found in murine fibroblasts (57) . Mouse EP 1 and EP 4 subtype receptors have been cloned by Ichikawa and colleagues (18, 54) . Interestingly, EP 4 was first cloned as an EP 2 receptor, but it was later shown to be sensitive to an EP 4 -specific ligand, AH-23848B (35) . Here, we chose two specific antagonists, AH-6809, an EP 1 subtype antagonist (8) , and AH-23848B, to block PGE 2 interaction with EP 4 subtype receptors (5) . Both of them reduced seruminduced 3T6 fibroblast growth in a dose-dependent manner, and almost blocked cellular proliferation, without showing cytotoxicity at the concentrations and for the incubation times used. In fact, when treatments were withdrawn, cells recovered the growth. However, higher doses of the EP 1 antagonist were required to block cellular proliferation. This may be due to the lower affinity of AH-6809 for the mouse EP 1 receptor, compared with its affinity for the human receptor (54) . These results agree with recent studies suggesting that PGE 2 affects cellular proliferation and cancer development by interaction with specific subtype receptors. PGE 2 induces the expression of early response genes, such as c-fos, c-jun, jun B, and egr-1, leading to enhanced proliferation and/or differentiation of osteogenic precursors (60) . This effect is abolished by AH-23848B in a dose-dependent manner, suggesting that it is cAMP dependent (59) . The role of PGE 2 interaction with EP 1 subtype receptor in colon carcinogenenis has been reported with the use of EP 1 knockout mice (56) and an EP 1 -specific antagonist (55) . We have shown elsewhere that S-(ϩ)-ketoprofen, a dual inhibitor of both cyclooxygenase isoforms, significantly reduces the serum-induced synthesis of PGE 2 in 3T6 fibroblasts and cell growth in a dose-dependent manner (42) . However, this inhibition reaches a plateau at 50-60% (maximum inhibition). Here, the EP 1 and EP 4 antagonist treatment almost blocked 3T6 fibroblast growth. When the synthesis of prostaglandins is abolished by a cyclooxygenase inhibitor, the AA released after mitogenic stimuli by PLA 2 s can be metabolized by lipoxygenases and cytochrome P-450 enzymes. Some lipoxygenase and cytochrome P-450 monoxygenase AA metabolites have been shown to activate protein kinase C and members of the mitogen-activated protein kinase family (4, 32, 49) . The mitogenic effect of other AA metabolites, which can be formed when the synthesis of PGs is blocked, may explain the distinct effect of PGHS inhibitors and PGE 2 antagonists on 3T6 cell proliferation. Further studies should be performed to clarify the role of lipoxygenase and cytochrome P-450 pathways on 3T6 fibroblast growth.
In the present study, we also provide evidence that the EP 1 and EP 4 antagonists differentially affect 3T6 fibroblast cycle progression, suggesting that PGE 2 reg- ulates cellular proliferation at various levels of the cell cycle machinery through its interaction with specific subtype receptors, thus modifying different second messenger levels. The EP 4 antagonist caused an early S-phase arrest of 3T6 fibroblasts, whereas the EP 1 antagonist-treatment of these cells was associated with a significant increase in G 0 /G 1 population with respect to control cells. However, we cannot rule out the presence of EP 2 or EP 3 receptors in 3T6 fibroblasts and their contribution to the control of their growth, because it has been described in other cell types (18, 24) . The hypothesis that PGE 2 regulates the cell cycle at different levels by interacting with specific subtype receptors also was supported by the data on the effect of AH-6809 and AH-23848B on cyclin levels. Thus the increase in G 0 /G 1 population of 3T6 fibroblast cultures induced by the EP 1 antagonist was linked to a decrease in cyclin D and E protein levels, and the early S-phase arrest induced by the EP 4 antagonist was linked to a significant decrease in cyclin A levels. Progression of the cell cycle through G 1 is governed by cyclin D-Cdk4/6 complexes in early G 1 and by cyclin E-Cdk2 complexes in late G 1 (for review, see Ref. 15) . Thus the lower levels of cyclins D and E may explain the G 0 /G 1 arrest induced by the EP 1 antagonist in our experimental conditions. On the other hand, cyclin A, an S-phase cyclin, is also essential for the progression of the mammalian cell cycle. First, the complex cyclin A-Cdk2 binds and phosphorylates the replication protein A, which is critical for DNA replication (14) . Second, cyclin A2 forms a complex with the E2F family of transcription factors during S phase and regulates its transcriptional activity (58) . Phosphorylation of E2F-bound DP1 by cyclin A-Cdk2 leads to suppression of E2F-1 DNA-binding activity, resulting in the transit of cells through the S-phase checkpoint (25) . Dysfunctional cyclin A-Cdk2-E2F-1 interaction during S phase leads to arrest in early S phase (25, 50) . These findings agree with the early S-phase arrest found in 3T6 fibroblasts after AH-23848B treatment that may result from the decrease in cyclin A levels. Previous studies have shown that PGF 2␣ induced cyclin D1 expression and DNA synthesis in 3T3 cells (44) , but to our knowledge this is the first report on PGE 2 controlling progression through different phases of the cell cycle by interacting with two different subtype receptors.
The cellular response to PGE 2 is controlled by changes in second messenger levels, induced by its interaction with its receptors. The EP 1 receptor mediates PGE 2 -induced elevation of free Ca 2ϩ with a barely detectable phosphatidylinositol response (54) , suggesting that it may regulate Ca 2ϩ channels via an unidentified G protein. In turn, the EP 4 receptor is coupled to G s and increases cAMP concentration by activation of adenylyl cyclase (9) . However, little is known about the role of PGE 2 in regulating progression through the cell cycle by its interaction with its distinct subtype receptors. Our studies suggest that PGE 2 controls cellular proliferation via [Ca 2ϩ ] i and cAMP. Both messengers seem to be crucial at different stages of the cell cycle. Thus 6-h thapsigargin treatment partially counteracted the G 0 /G 1 arrest of 3T6 fibroblasts induced by AH-6809, suggesting a role for Ca 2ϩ levels in the transition from G 0 to G 1 and S phases and, consequently, the growth arrest induced by the EP 1 antagonist. These results agree with the findings of Morris et al. (31) , who found that Ca 2ϩ and calmodulin were necessary for G 1 progression in fibroblasts. Calmodulin kinase II inhibition reduced cyclin D1 levels, causing G 1 arrest in NIH/3T3 cells. The lower cyclin E levels that we also have found may be a consequence of the decrease in cyclin D levels, because cyclin E transcription is activated when pRb is hyperphosphorylated by the complexes cyclinD-Cdk4/6 and no longer inhibits E2F/DP. cAMP may be involved in S-phase progression of 3T6 fibroblasts by regulating cyclin A levels. The intracellular levels of cyclin A protein are regulated mainly at the levels of transcription and/or mRNA stability (28) . The human and mouse cyclin A genes have recently been cloned and their promoters analyzed (19) . The cyclin A ATF site is bound by activating transcription factor-1 (ATF-1) and the cAMP-response element binding protein (CREB), which function as positive regulators of the cyclin A promoter. This transcription factor binds to its corresponding site and mediates the stimulatory effect of a cAMP analog on cyclin A gene transcription in human fibroblasts (10) . The activity of ATF-1 and CREB also is regulated by their phosphorylation status (21) . Indeed, transforming growth factor-␤1, which inhibits proliferation of most normal cell types (1), induces growth arrest in mink lung epithelial cells by decreasing the phosphorylation of CREB and ATF-1 and thus downregulating cyclin A promoter activity. However, the role of cAMP in cell proliferation seems to be controversial. In certain cell lines it behaves as a mitogenic stimulus (40) , whereas in other cell types it induces cell cycle arrest (53) . Our results agree with those of Lee et al. (27) and Desdouets et al. (11) , who suggested that cAMP regulates cyclin A levels. Therefore, the contribution of the cAMP signaling pathway to cell growth may thus depend on both cell type and cell cycle status.
In conclusion, we provide evidence indicating that the effect of PGE 2 interaction with EP 1 and EP 4 subtype receptors on 3T6 fibroblast progression is associated with changes in specific cyclin levels, which control cell cycle progression. EP 1 and EP 4 antagonists decreased cyclin D, E, and A protein levels, the respective first levels of regulation of Cdk-4, Ckd-6, and Cdk-2 activity. These changes may explain the cell cycle arrest induced by these antagonists in G 0 /G 1 and S phases, respectively. However, we cannot rule out the involvement of other cell cycle regulators, such as p27 (20) . Our results also suggest that two mediators, [Ca 2ϩ ] i and cAMP, control progression through G 0 /G 1 and S phases of the cell cycle, respectively, by PGE 2 interaction with EP 1 and EP 4 subtype receptors.
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